Healthcare

TYRA BIOSCIENCES INC

Ticker: TYRA
Exchange: US
Composite FIGI: BBG00RCQD9D1

Total Alternative Signals

1signals tracked

Weighted Sentiment

-0.10weighted index

Avg Materiality Score

3.0/ 5.0 scale

Signal Distribution

0|1|0

Alternative Data Signal Feed

Real-Time Ingestion Active

Unlock Alternative Signals Feed

Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for TYRA BIOSCIENCES INC. Programmatic API and Webhooks available.

Talent PivotNeutral
Filing Date: 2026-06-12

Signal Event Report - FIGI BBG00RCQD9D1

Tyra Biosciences announced a new board appointment, which was met with mixed analyst commentary. While there is optimism for dabogratinib, renewed skepticism surrounds the SURF-302 program and the company's reliance on a concentrated clinical pipeline.

Quantitative Investment Thesis

The long-term investment thesis is now more complex, as investors must weigh the potential strategic benefits of the new board appointment against the heightened pipeline risk from SURF-302 skepticism and the company's reliance on a single lead candidate. Future clinical data and pipeline diversification will be critical for sustained growth.

Materiality & Sentiment Scores
Sentiment: -0.1
Materiality: 3 / 5
Source Document: https://finance.yahoo.com/sectors/healthcare/articles/tyra-biosciences-tyra-too-reliant-011601309.html?.tsrc=rss